McKinnon, Ross A.
Cook, Matthew
Liauw, Winston
Marabani, Mona
Marschner, Ian C.
Packer, Nicolle H.
Prins, Johannes B.
Funding for this research was provided by:
Medicines Australia, with specific support from the Australian affiliates of Abbvie, Amgen, Eli Lilly, Janssen, Novo Nordisk, Roche and Sanofi
Article History
First Online: 17 January 2018
Compliance with Ethical Standards
:
: Ross McKinnon: Education and advisory service fees in relation to biosimilars for AbbVie and Sanofi Australia. Matthew Cook: Advisory board for Roche and Baxter. Winston Liauw: Advisory board for NPS MedicineWise. Mona Marabani: Consultancy, speaker fees or conference support from AbbVie, BMS, UCB, MSD, Pfizer, Janssen, Novartis and Sanofi. Ian Marschner: Research grant and consulting fees from Janssen-Cilag and consulting fees from Pfizer, AbbVie and Generic Health. Nicolle Packer reports having no conflicts of interest. John Prins holds clinical and scientific advisory board positions and/or has received speaking fees from Pfizer, Merck and Novo Nordisk.